National Trends in Ambulatory Asthma Treatment, 1997–2009
- 226 Downloads
Despite reductions in morbidity and mortality and changes in guidelines, little is known regarding changes in asthma treatment patterns.
To examine national trends in the office-based treatment of asthma between 1997 and 2009.
PARTICIPANTS AND DESIGN
We used the National Ambulatory Care Survey (NAMCS) and the National Disease and Therapeutic Index™ (NDTI), nationally representative audits of office-based physicians, to examine patients diagnosed with asthma less than 50 years of age.
Visits where asthma was diagnosed and use of six therapeutic classes (short-acting β2 agonists [SABA], long-acting β2 -agonists [LABA], inhaled steroids, antileukotrienes, anticholinergics, and xanthines).
Estimates from NAMCS indicated modest increases in the number of annual asthma visits from 9.9 million [M] in 1997 to 10.3M during 2008; estimates from the NDTI suggested more gradual continuous increases from 8.7M in 1997 to 12.6M during 2009. NAMCS estimates indicated declines in use of SABAs (from 80% of treatment visits in 1997 to 71% in 2008), increased inhaled steroid use (24% in 1997 to 33% in 2008), increased use of fixed dose LABA/steroid combinations (0% in 1997 to 19% in 2008), and increased leukotriene use (9% in 1997 to 24% in 2008). The ratio of controller to total asthma medication use increased from 0.5 (1997) to a peak of 0.7 (2004). In 2008, anticholinergics, xanthines, and LABA use without concomitant steroids accounted for fewer than 4% of all treatment visits. Estimates from NDTI corroborated these trends.
Changes in office-based treatment, including increased inhaled steroid use and increased combined steroid/long-acting β2-agonist use coincide with reductions in asthma morbidity and mortality that have been demonstrated over the same period. Xanthines, anticholinergics, and increasingly, LABA without concomitant steroid use, account for a very small fraction of all asthma treatments.
KEY WORDSprimary care respiratory disease pharmacotherapy
The statements, findings, conclusions, views, and opinions contained and expressed in this article are based in part on data obtained under license from the following IMS Health Incorporated information service(s): National Disease and Therapeutic Index™ (1997–2009), IMS Health Incorporated. All Rights Reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IMS Health Incorporated or any of its affiliated or subsidiary entities.
Dr. Alexander is supported by the Agency for Healthcare Research and Quality (K08 HS15699-01A1; RO1 HS0189960) and the Robert Wood Johnson Physician Faculty Scholars Program. The funding sources had no role in the design and conduct of the study, analysis or interpretation of the data; and preparation of final approval of the manuscript prior to publication.
Conception and design: GCA and RSS; Analysis and interpretation: ASH, SZ, GCA, and RSS; Manuscript drafting: GCA; Substantive manuscript revision: ASH, SZ, GCA, and RSS; Approval of final manuscript: ASH, SZ, GCA, and RSS; Study supervision: GCA
Conflicts of Interest
Dr. Alexander is a consultant for IMS Health.
- 2.American Lung Association Epidemiology and Statistics Unit. Trends in Asthma Morbidity and Mortality, February 2009.Google Scholar
- 4.Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma---United States, 1980--1999. In: Surveillance Summaries, March 29, 2002.MMWR 2002;51(No. SS-1):1--13.Google Scholar
- 5.Center for Disease Control and Prevention, National Health Interview Survey, National Center for Health Statistics, CDC. Compiled 3/18/2008. Accessed 2/9/2010Google Scholar
- 6.National Heart, Lung and Blood Institute. Chartbook on Cardiovascular, Lung and Blood Diseases, U.S. Department of Health and Human Services. National Institute of Health 2009.Google Scholar
- 7.Saltpeter S, Buckley N, Ormiston T, Salpeter E. Meta-analysis: effect of long-acting β2-agonists on severe asthma exacerbations and asthma-related deaths. Ann Int Med. 2006;144:904–12.Google Scholar
- 8.Donohue J, Fromer, L. Long-acting beta-agonists: role in asthma management. J Fam Pract. 2006 Apr;Suppl:1–6.Google Scholar
- 9.US Food and Drug Administration Website. FDA Public Health Advisory. Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol xinafoate powder), Foradil Aerolizer (formoterol fumarate inhalation powder). Available at: http://www.fda.gov/cder/drug/advisory/laba.htm. Accessed February 9, 2010.
- 10.National Heart Lung and Blood Institute. Expert Panel Report 3: guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed February 9 2010.
- 13.National Ambulatory Care Medical Survey. Available at: http://www.cdc.gov/nchs/ahcd/trend_analysis.htm (Accessed June 20, 2011).
- 14.Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Bethesda: National Heart, Lung, and Blood Institute; 2002.Google Scholar
- 15.National Asthma Education and Prevention Program: Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. Summary Report 2007. National Heart, Lung, and Blood Institute. NIH Publication Number #08-5846. October 2007.Google Scholar
- 17.Zell ER, McCaig LF, Kupronis BA, Besser RE, Schuchat A. A comparison of the National Disease and Therapeutic Index and the National Ambulatory Medical Care Survey to evaluate antibiotic usage. In: Proceedings of the survey research methods section, American Statistical Association (2000). Alexandria (Virginia): American Statistical Association. Available: http://www.amstat.org/sections/srms/Proceedings/papers/2000_143.pdf. (Accessed June 20, 2011).